Attendee search 

IMI Consulting is Europe’s leading Management Consultancy and Advisory in Life Sciences having a track-record of over 27 years in servicing its clients.  Because of IMI’s 150 Associate Partner network, it provides most forms of transaction and therapeutic expertise on a worldwide basis:

Strategy Development (market intelligence, development of new ways to compete, pipeline and segment analysis, Market Access and Pricing, Strategic Plans and Planning, etc.), Transaction Support (usually as implementation of the strategy, BD&L, Mergers & Acquisitions including spin-outs ) and Capital Raising.

IMI raises capital from seed to Round C, from VCs to private investors (HNW-angels).

Its 150 Associate Partner base allows specialization in most therapeutic sectors servicing Big & Specialty Pharma, Biotech, Diagnostic, MedTech, e-health and OTC/Nutritionals:

Addiction, Analgesics, Rheumatoid Arthritis, Cancer, Cardiovascular, CNS, Dermatology, Endocrinology, Gynecology, Urology, Gastrointestinal, Hematology, Life-Cycle Management, Metabolic, Molecular Diagnostics, Respiratory, Robotics, Genetic Editing, Nutritionals, OTCs, Transplantation, etc.

We cover all of Europe, USA and Asia.

IP Law Firm

Circassia: specialty respiratory pharmaceutical and medical device company

Circassia is building a world-class, specialty pharmaceutical and medical device company focused on respiratory disease and we have our own direct sales and support infrastructure in US, UK and Germany, and we are expanding our team in China where we expect to have 90 people in place by the end of 2018.

We have a collaboration with AstraZeneca in the US to market Tudorza (aclinidium DPI) for COPD and expect to launch Duaklir (aclidinium/formoterol DPI) in 2019, following the recent filing with FDA.  We also market our own NIOX asthma management devices in 35 markets, either via our own sales teams or distributors.

In-licensing or acquisition targets

We are actively looking for new pharmaceutical products/devices in US, China and Europe.  Our targets are late stage or marketed products that are either in respiratory or allied fields, or which can be supported by a small focused sales team.  We would also consider products that share a common physician call point.

Out licensing opportunities

We are also looking for partners who we can work with to progress our development pipeline that comprises direct substitutes for leading asthma and COPD products, as well as a number of treatments based on novel formulations of currently approved drugs.

Circassia is highly responsive and flexible and is open to a wide range of deal structures from promotion deals through licensing to acqusition.

Circassia: specialty respiratory pharmaceutical and medical device company

Circassia is building a world-class, specialty pharmaceutical and medical device company focused on respiratory disease and we have our own direct sales and support infrastructure in US, UK and Germany, and we are expanding our team in China where we expect to have 90 people in place by the end of 2018.

We have a collaboration with AstraZeneca in the US to market Tudorza (aclinidium DPI) for COPD and expect to launch Duaklir (aclidinium/formoterol DPI) in 2019, following the recent filing with FDA.  We also market our own NIOX asthma management devices in 35 markets, either via our own sales teams or distributors.

In-licensing or acquisition targets

We are actively looking for new pharmaceutical products/devices in US, China and Europe.  Our targets are late stage or marketed products that are either in respiratory or allied fields, or which can be supported by a small focused sales team.  We would also consider products that share a common physician call point.

Out licensing opportunities

We are also looking for partners who we can work with to progress our development pipeline that comprises direct substitutes for leading asthma and COPD products, as well as a number of treatments based on novel formulations of currently approved drugs.

Circassia is highly responsive and flexible and is open to a wide range of deal structures from promotion deals through licensing to acqusition.